In the early 2000s, insider trading scandals in the pharmaceutical industry drew widespread attention, notably involving ImClone’s former CEO Sam Waksal. Waksal sold shares of his company after learning that the US Food and Drug Administration (FDA) had rejected its main cancer drug application, prompting a sharp decline in stock value once the news became public. Family members connected to Waksal also sold shares but faced no criminal charges. The case later ensnared lifestyle guru Martha Stewart, who was convicted for lying during the investigation.

These historical episodes underscore concerns surrounding Kalshi’s recent announcement that it will offer betting contracts based on FDA drug approval decisions and clinical trial outcomes. The prediction market intends to require participants to disclose their employers and exclude individuals employed by pharmaceutical companies or those with access to unblinded clinical trial data. Betting will only commence after trial enrolment closes, aiming to reduce opportunities for insider trading.

Kalshi argues that these event-based contracts will enhance market transparency by providing competitors and the public with better insights into a critical industry while catering to traders interested in specific drug milestones rather than broader stock price movements. Robert DeNault, Kalshi’s enforcement director, emphasized the company’s focused approach to monitoring bets, stating that material information related to these contracts is narrowly defined and known to a limited group, which facilitates targeted surveillance.

This approach extends beyond the pharmaceutical sector. Last week, Kalshi disclosed it had frozen the account of Donald Trump’s longtime teleprompter operator, who allegedly used inside information about the president’s speeches to place bets on their content. This incident highlights the challenges faced by Kalshi amid practices in Washington, where some members of Congress routinely trade stocks influenced by their official actions. Additionally, an offshore rival to Kalshi, Polygroup, reportedly discussed charging traders substantial fees for expedited access to presidential posts on the social media platform Truth Social, a move critics compare to controversial high-frequency trading privileges.

Such privileged access is notable as it relates to government officials’ public statements, which have been shown to influence markets significantly. While the Trump-linked teleprompter operator’s case has yet to result in criminal charges, it exemplifies the risks of insider trading when information flows intersect with prediction markets.

Regulatory enforcement has appeared to decline under the current administration. The Commodity Futures Trading Commission (CFTC), where Kalshi reports suspected insider trading, saw its enforcement actions drop sharply from 58 cases in the last full fiscal year under the previous administration to 13 in fiscal year 2025. Likewise, the Securities and Exchange Commission (SEC) recorded a decrease in insider trading and market manipulation cases from 54 to 48, with total enforcement actions falling by 22 percent.

Leaders of both the CFTC and SEC maintain commitments to robust oversight and investor protection. However, prosecutions tied specifically to prediction market abuses remain rare. The few cases include a military service member accused of misusing classified information about a Venezuelan operation and a Google engineer charged with betting on search engine trends; both individuals are contesting the allegations.

While market platforms like Kalshi deploy advanced detection tools and enforce participant restrictions, experts warn that without effective government enforcement, the misuse of insider information will continue to challenge market integrity. As prediction markets expand into more sectors, the potential for exploitation of privileged information may grow accordingly.